3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Carcinoma, Basal Cell
14
Neoplasms
4
Pancreatic Neoplasms
3
Skin Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Medulloblastoma
2
Colorectal Neoplasms
2
Chondrosarcoma
2
Basal Cell Nevus Syndrome
2
Urinary Bladder Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Solid Cancers
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rhabdomyosarcoma
1
Pancreatic Diseases
1
Osteosarcoma
1
Odontogenic Cysts
1
Neurofibrosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Unknown Primary
1
Neoplasms, Basal Cell
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Interventions
Paclitaxel
6
Carboplatin
6
Gemcitabine
3
pembrolizumab
2
Irinotecan
2
Erlotinib Hydrochloride
2
Capecitabine
2
Bevacizumab
2
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
etoposide phosphate
1
erythromycin propionate-N-acetylcysteinate
1
entrectinib
1
cobimetinib
1
belinostat
1
atezolizumab
1
antineoplaston AS 2-1
1
antineoplaston A10
1
alectinib
1
Vemurafenib
1
Surveys and Questionnaires
1
Oxaliplatin
1
HhAntag691
1
Everolimus
1
Etoposide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neoplasms, Unknown Primary
×
HhAntag691
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts